Ozureprubart
Monoclonal antibody
Also known as GSK6775388
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
No clinical trials on ClinicalTrials.gov
No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.
No registered studies found. Not yet ingested, or none registered.
Competitive landscape
Other IgE drugs
1 other tracked programme targets this mechanism.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ozureprubart: this drug | Stage not on record | Monoclonal antibody | IgE | not yet graded | No reviewed efficacy summary | |
| Omalizumab (Xolair) | Approved(overall) | Monoclonal antibody | IgE (immunoglobulin E), IgE | Partial signal | NCT03881696: Number of Participants by Stage 1 Treatment Assignment, Omalizumab Versus Placebo, Who Successfully Consume a Single Dose of ≥600 mg of Peanut Protein Without Dose-Limiting Symptoms During the DBPCFC Conducted at the End of Treatment Stage 1 (During the DBPCFC at the end of Stage 1: 16 to 20 weeks after Stage 1 treatment initiation): Omalizumab — Success: 79 Participants; Failure: 39 Participants | Placebo for Omalizumab — Success: 4 Participants; Failure: 55 Participants NCT01287117: Change From Baseline to Week 12 in the Weekly Itch Severity Score (Baseline to Week 12): Placebo -3.63 Units on a scale (Standard Deviation 5.22) | Omalizumab 75 mg -6.46 Units on a scale (Standard Deviation 6.14) | Omalizumab 150 mg -6.66 Units on a scale (Standard Deviation 6.28) | Omalizumab 300 mg -9.4 Units on a scale (Standard Deviation 5.73) |
Upcoming events
No upcoming readouts on record for this asset.